
Novo A/S used to focus on companies in the early commercialization phases, but a change of that strategy to a focus on bigger and more mature companies led to the divestiture of British-based Archimedes Pharma.
“Our strategy going forward is to invest in some bigger and more mature companies than Achimedes. [The investment in Archimedes] came as the result of a different strategy where we focused on companies in the early commercialization phases. But we have moved away from that, so we chose to sell Archimedes. But also because the timing was right, both for the specific company and because the market is generally positive,” Eivind Kolding, CEO in Novo A/S, tells Medwatch.
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app